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A B S T R A C T
Biomarkers can be categorised from type 0 (genotype or phenotype), through 6 (clinical scales), each level
representing a part of the processes involved in the biological system and drug treatment. This classification
facilitates the identification and connection of information required to fully (mathematically) model a disease
and its treatment using integrated information from biomarkers. Two recent reviews thoroughly discussed the
current status and development of biomarkers for epilepsy, but a path towards the integration of such
biomarkers for the personalisation of anti-epileptic drug treatment is lacking. Here we aim to 1) briefly
categorise the available epilepsy biomarkers and identify gaps, and 2) provide a modelling perspective on
approaches to fill such gaps. There is mainly a lack of biomarker types 2 (target occupancy) and 3 (target
activation). Current literature typically focuses on qualitative biomarkers for diagnosis and prediction of
treatment response or failure, leaving a need for biomarkers that help to quantitatively understand the overall
system to explain and predict differences in disease and treatment outcome. Due to the complexity of epilepsy,
filling the biomarker gaps will require collaboration and expertise from the fields of systems biology and systems
pharmacology.
1. Introduction
A large unmet medical need exists for the 50 million people with
epilepsy worldwide, as up to 30% of them are not satisfactorily treated
(Ngugi et al., 2010; Sillanpää and Schmidt, 2006). A major cause of
dissatisfactory anti-epileptic drug (AED) treatment outcome is large
inter- and intra-individual variability in pharmacokinetics (PK), phar-
macodynamics (PD), and pathophysiology (van Dijkman et al., 2016).
To better understand and explain such variability, biomarkers are
needed. For epilepsy, biomarkers have been defined as “an objectively
measurable characteristic of a biological process that reliably identifies the
development, presence, severity, progression, or localization of an epilepto-
genic abnormality” which would suggest only a minor focus on the
biological features of a treatment effect (Pitkänen and Engel, 2014).
Two recent reviews provided an overview of the available epilepsy
biomarkers (Pitkänen et al., 2016; Walker et al., 2016). Pitkänen et al.
stated that “Biomarker discovery could be regarded as an advance in the
personalisation of medicine, and could allow prevention in the right person
at the right time, rather than just symptomatic treatment”. However,
biomarker data alone will not automatically lead to personalised
medicine. PK, PD and disease models, in conjunction with individual
patient data, are required to estimate patient-specific parameters and
make subsequent treatment choices (Knibbe and Danhof, 2011;
Standing, 2016). Furthermore, the use of biomarkers can result in a
more effective and structured drug development process (Cohen et al.,
2015).
A classification system exists that categorises biomarkers with
regard to their place in modelling PK, PD and disease processes
(Danhof et al., 2005), in terms of cascading types; type 0 (genotype
or phenotype), type 1 (drug concentration), type 2 (target occupancy),
type 3 (target activation), type 4 (physiological response), type 5
(pathophysiological response), and type 6 (clinical scales). Each type
represents part of the interactions between (patho-) physiology and
treatment, which, if adequately described, would allow for the predic-
tion of in vivo drug effect based on intermediary biomarkers (Fig. 1.).
Categorisation of the available epilepsy biomarkers according to this
system may aid in the identification of biomarker gaps, and help to
determine a way forward in the use of epilepsy biomarkers for
personalised medicine and drug development. The aims of this review
are therefore to 1) briefly categorise the available epilepsy biomarkers
and identify gaps, and 2) provide a modelling perspective on ap-
proaches to fill such gaps.
2. Available Biomarkers
2.1. Type 0 – Genotype or Phenotype
Many genes have been discovered that increase the risk of devel-
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oping epileptic seizures or alter the chance of responding to drug
therapy (Rossignol et al., 2014; Myers and Mefford, 2015; Pitkänen
et al., 2016; Walker et al., 2016). These include the genes that encode
for Na+ channels, Ca2+ channels, K+ channels, and the nicotine-
acetyl-choline- and GABAA receptors. Some examples of such genetic
markers are genetic differences in serotonergic transmission related to
the occurrence of temporal lobe epilepsy and epileptogenesis following
traumatic brain injury with subsequent changes in GABAergic expres-
sion. Epileptic seizures are based on excessive synchronised neuronal
excitations, and thus it comes to no surprise that genes related to either
increased excitation or decreased inhibition are implicated in seizure
susceptibility. Neuro-inflammation is considered an important factor in
epileptogenesis after traumatic brain injury or stroke. Genetic markers
for CD40, a costimulatory protein found on antigen presenting cells that
is required for their activation, interleukins, and oxidative stress seem
to support this. Most likely these genes are not single contributors to
risk, but part of a large network of interacting genes, some innocuous
on their own, and other factors eventually leading to epileptogenesis.
MicroRNA, or miRNA, are small non-coding RNA molecules in-
volved in post-transcriptional gene regulation and gene silencing. Some
of these miRNA circulate through the body and thereby provide a
bridge between genetic expression, either normal expression of mutated
genes, or abnormal expression of otherwise normal genes, and clinical
presentation. Two miRNAs, hsa-miR-487a and hsa-miR-9a-3p, have
been found to correlate to neuro-inflammation and epileptogenesis,
which perhaps one day could allow clinicians to determine if immuno-
suppression for the prevention of epileptogenesis is indicated in their
patient (Zucchini et al., 2014; Roncon et al., 2015). The miRNA hsa-
miR-106b-5p, part of an miRNA family implicated in cell proliferation,
was found to diagnose idiopathic generalised epilepsy at a sensitivity
and specificity of 80% and 81% respectively (Wang et al., 2015).
2.2. Type 1 – Drug Concentration
For infectious diseases, therapeutic drug monitoring (TDM) of
antibiotic plasma concentrations is commonly used to assure sufficient
drug exposure; plasma concentrations are considered representative for
the antibiotic target site. In AED therapy, plasma AED concentrations
are theoretically simple biomarkers, yet much controversy exists
regarding its use in clinical practice. Objections to plasma PK optimisa-
tion of AED therapy include the lack of a clear correlation between
plasma concentrations and AED therapy outcome in the individual
patient in the clinic, the burden on the patient, and the cost of sampling.
While target site exposure is undeniably the main driving force behind
efficacy, pharmacokinetic variability obscures the correlation between
dose, plasma concentration and target site concentration, and thereby
efficacy. Yet, plasma exposure has been shown to correlate to efficacy
for a number of AEDs (Nakashima et al., 2015; Ogusu et al., 2014;
Delattre et al., 2012; Van Den Broek et al., 2012; Girgis et al., 2010),
suggesting that clinical titration to a certain efficacious level of systemic
exposure may still be optimised by TDM (van Dijkman et al., 2017b),
especially in the face of polytherapy (van Dijkman et al., 2017a).
Few studies have investigated the correlation between plasma and
cerebrospinal fluid (CSF) or target site AED concentrations in humans.
In 22 pharmacoresistant patients undergoing epileptic focus resection,
large differences in AED concentrations were found between plasma,
medial temporal gyrus dialysate, and excised tissue (Rambeck et al.,
2006). However, plasma and CSF concentrations of topiramate were
highly correlated in a group of 14 regular, non-pharmacoresistant
patients (Christensen et al., 2001). Finally, one study showed parallel
profiles of valproic acid concentrations in plasma, CSF, and extracel-
lular fluid (ECF), albeit not at the same concentration level (Lindberger
et al., 2001). These three studies suggest that regular patients' AED
concentrations in CSF, and possibly at the target site, can be seen as a
simple ratio of plasma concentrations, whereas CSF concentrations in
non-responding patients may not show the same correlation, requiring
more elaborate methods for determining target site exposure. For the
moment, evidence is too limited for it to be used in clinical decision
making, or in drug development to determine the source of inadequate
response.
As an alternative to CSF sampling, total or local brain AED
concentrations could be measured by positron emission tomography
(PET) (Kim et al., 2010; Syvänen et al., 2013). Such an intensive PK
analysis and optimisation is not indicated in the patient that responds
well to initial drug titration, but may still be indicated for refractory or
non-responding patients to differentiate between failure to reach
adequate target site exposure and failure to respond pharmacodynami-
cally. Inadequate target site exposure could be adjusted for by dose
adjustments or blood-brain barrier (BBB) manipulation, for example by
Pgp inhibition (Clinckers et al., 2005), whereas pharmacodynamic
failure would require switching to another AED or add-on therapy.
Although an intensive PK workup (i.e. determining an individual's
systemic, and possibly cerebral concentrations) incurs extra costs and
burden, it should be offset against the costs of hospital admissions,
missed work days, and other adverse results from seizures or severe side
effects in non-responding patients. In well-responding patients, it is still
highly recommended to measure drug plasma concentrations, to be able
to differentiate between inadequate exposure due to changes in PK, the
development of pharmacoresistance, or non-compliance in patients that
becomes treatment resistant at a later time (Patsalos et al., 2008). Some
of the burden of plasma sampling may be preventable by substituting it
with the newer, lesser invasive techniques like dried blood spot and
saliva sampling, which have seen some increased interest in recent
years (Milosheska et al., 2015; Patsalos and Berry, 2013), but would
add another source of variability to the analysis.
2.3. Type 2 – Target Occupancy & Type 3 – Target Activation
Target occupancy is a major determinant in drug efficacy, but few
suitable biomarkers are available. In vitro binding kinetics, investigated
for many AEDs, are not directly translatable to in vivo. PET occupancy
studies can be performed to investigate target occupancy in vivo, but it
requires at least 12 research subjects, and two PET scans per individual
(Zhang and Fox, 2012), making it impractical for AED therapy
personalisation in the clinic and very costly for drug development.
Further complicating binding kinetics, it has been proposed that
epilepsy may structurally or functionally modify target sites, for which
no biomarker is currently available (Beck, 2007).
Once a target has been occupied, it should translate into an
activation of the cellular processes that are involved in the treatment
effect. Important to some of these processes is the second messenger
cAMP, which is central to the phosphorylation of ion channels
(Misonou et al., 2004), but is also implicated in epileptogenesis (Zhu
et al., 2012). As these processes take place inside the cell, measuring
them is highly invasive in in vivo situations. Alternatively, products that
are a direct result of activation and readily cross the BBB, such as
Fig. 1. Diagram of a “cascading” PK/PD model for the prediction of in vivo drug effects based on intermediary biomarker responses. Reproduced with permission from (Danhof et al.,
2005).
S.C. van Dijkman et al. European Journal of Pharmaceutical Sciences 109 (2017) S47–S52
S48
miRNA's, could be measured peripherally. For example, miRNA has-
miR-301a-3p was found to correlate to AED resistance in a study of
drug-resistant patients, drug-responsive patients, and healthy controls,
which may imply its down-stream role after target activation (Wang
et al., 2015). As their patients were already drug-resistant, it cannot be
determined if this miRNA was part of the cause or effect of drug-
resistance. Some evidence exists for the so-called use-dependent block-
ing effects of AEDs, resulting in a higher AED effect at higher levels of
neuronal activity (Beck, 2007), which may be quantified by an electro-
encephalogram (EEG), hot glucose PET, or functional magnetic reso-
nance imaging (fMRI).
2.4. Type 4 – Physiological Response & Type 5 – Pathophysiological
Response
Neuro-inflammation plays a role in epileptogenesis and is a result of
seizure activity, making biomarkers that can detect it at an early stage
highly valuable in both prevention and treatment. PET can visualise
neuro-inflammation by targeting the peripheral benzodiazepine recep-
tor (PBR), otherwise known as translocator protein 18 kDa (TSPO),
expressed in many parts of the body, amongst which microglia. In the
post-status epilepticus model TSPO peaks around 2 weeks after the
initial status epilepticus (Galovic and Koepp, 2016; Bogdanović et al.,
2014). TSPO binding is also increased in foci of pharmaco-resistant
patients with focal-onset epilepsy (Gershen et al., 2015). So far, no
quantitative data is available to support setting threshold levels of
neuro-inflammation above which anti-inflammatory treatment is in-
dicated. Some miRNAs may be involved in neuro-inflammation by
regulating interleukin 1β, cell adhesion molecules, and neuronal
growth (Henshall et al., 2016). How well these miRNAs monitor
response in terms of neuro-inflammation (and subsequent neuronal
damage) in the clinical setting is as of yet unclear and needs to be
further investigated.
Cerebral micro damage due to seizure activity may contribute to
disease progression, either due to kindling (i.e. seizures initiate a
pathological process of inflammation and dysregulated neuronal
growth leading to sustained seizures) or worsening of existing patho-
physiology. fMRI characterises brain region activity, active seizure foci
and/or inflammation (Olszewska and Costello, 2014). It can also be
coupled to EEG to increase its accuracy of locating epileptic foci and
determining the involvement of different brain structures (Gotman and
Pittau, 2011). Diffusion tensor imaging (DTI) traces nerve fibres,
thereby illustrating structural connectivity and hierarchical structure,
which may be affected both as a cause and as a result of epilepsy (Gong
et al., 2009; Iturria-Medina et al., 2008). BBB disruption occurs during
and after seizures, which has a significant impact on cerebral AED
concentrations. Dynamic contrast enhanced MRI is able to quantify this
BBB disruption, it can track epileptogenesis, and may one day help the
physician to determine dose adjustments when a change in cerebral
AED exposure is due to changes in BBB permeability or transport.
Brainwaves on an EEG are a direct result of micro processes that are
otherwise difficult to measure, allowing insight in the underlying
physiology. Standard EEG is non-invasive, does not present a large
burden to the patient, and is inexpensive in terms of equipment or
application. Interpretation of EEG signals, however, can be time
consuming and requires a trained professional with expert knowledge,
although advances in machine-based EEG analysis and interpretation
are slowly eliminating these issues. A limitation of the use of EEG in the
clinic is the reliance on EEG characteristics that were discovered when
EEGs could only be analysed with the naked eye, such as high-
frequency oscillations, focal slowing, spindles, etc., while these char-
acteristics are not very sensitive to drug effect. Slow adoption of
pharmaco-EEG (PEEG) has been attributed to its unreliable transla-
tional accuracy, a lack of standardised operating procedures (SOPs),
and large inter-individual variability (Jobert et al., 2013). Methodolo-
gies more sensitive to microphysiology and treatment effect are being
developed, such as beta wave spectral power correlations with GABA-
ergic inhibition in AED use (Lopes da Silva, 2002).
2.5. Type 6 – Clinical Response
The definition of response to AED treatment is ill-defined and may
differ between patient, physician, and clinical researcher. Typically,
clinical response is a reduction in seizures, but patient and physician
may disagree on what would qualify as a satisfactory reduction, and the
impact of side effects may be underestimated, possibly leading to poor
adherence (Smithson et al., 2012). In clinical trials, treatment success is
defined as a reduction of at least 50% in seizure frequency between
baseline and end of the study. This binarisation and the reduction of
data leads to a large information loss, and unnecessarily complicates
the characterisation of correlations between AED dose, exposure, and
response, especially given the large variability between and within
individuals (van Dijkman et al., 2016).
3. Modelling Perspective
There is a simple adage that states: to measure is to know.
Quantification of the intricate mechanisms involved in the disease
and its therapy is required to allow optimal prevention, prognosis and
treatment. Hence, single biomarkers will not suffice to make informed
decisions in the clinic, nor in drug development. Instead, models that
integrate biomarkers across the entire range of types (Fig. 1) are
needed. In systems biology and systems pharmacology, problems are
considered as part of a network of interactions and complex mechan-
isms. Systems biology of epilepsy entails the quantification of physio-
logical and pathological processes, roughly corresponding to biomar-
kers types 0, 4 and 5. Systems pharmacology allows the quantification
of physiology-based (PB/)PK/PD, roughly corresponding to biomarker
types 1, 2, 3, and 6 (Danhof, 2016). Fig. 2, adapted from Sheiner
(Sheiner, 1997), depicts how a physician would determine the indivi-
dual patient's optimal treatment based on the dimensions of a treatment
regimen, its benefits, and the patient's prognostic factors. Whereas this
figure may adequately represent diseases with relatively few dimen-
sions, the number of dimensions in epilepsy treatment grows to levels
that can no longer be handled without the aid of computer algorithms.
Personalised medicine in epilepsy will ultimately require the combina-
tion of models from systems biology and systems pharmacology,
leading to systems medicine. Epilepsy biomarker literature generally
focuses on qualitative biomarkers that categorise patients for diagnosis
and prognosis, while systems medicine needs quantitative biomarkers
that aid in understanding the systems involved in disease and treatment
mechanisms. Using the biomarker classification system, gaps in bio-
markers were identified with regard to target occupancy and target
activation (Table 1, Fig. 3). Such biomarkers characterise how AED
Fig. 2. Example of a simple therapeutic response surface, relating patient prognostic
factors and dose regimen to benefit, as net utility of efficacy and toxicity. The best
regimen for your patient corresponds to the maximum of the surface on the benefit axis.
Adapted with permission from (Sheiner, 1991).
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exposure at or inside the neuron translates to changes in (patho-)
physiology, and thus are essential to determine the cause of pharma-
coresistance. Although biomarkers were found that relate to epilepto-
genesis and prognosis, these did not provide quantitative data allowing
the modelling of disease predisposition, generation, and progression. In
the following sections we present modelling approaches that may
augment the use of existing biomarkers, or reduce the need for
biomarkers.
3.1. From Dose to Target Site Concentrations
Covariates such as weight, age, sex, comedication, drug binding and
cytochrome P450 polymorphisms strongly influence dose to plasma PK
and can be pre-emptively adjusted for using PK models, resulting in a
more personalised medicine compared to current weight-based dosing
algorithms (Knibbe and Danhof, 2011). A greater challenge is to relate
concentrations in plasma to those available for interaction at the target
site. Much progress has been made on the PBPK modelling of
concentrations in plasma and local brain areas (Westerhout et al.,
2012; de Lange and Hammarlund-Udenaes, 2015; Yamamoto et al.,
2016), based on the Mastermind Approach (Fig. 4) (de Lange, 2013).
These models, developed on preclinical data, have been shown, as
proof-of-concept, to translate well to humans. Where information was
available on human drug concentrations in particular brain compart-
ments (such as lateral ventricle CSF, lumbar spine region, or brain
extracellular fluid) this could be adequately predicted by the generic
PBPK model after translation of the rat physiological parameter values
to the human values. This could replace the need for large invasive
studies in humans, although at this stage, it may still require lumbar
punctures to measure drug concentrations in CSF for increased accuracy
for the individual patient.
3.2. From Target Site Concentrations to Target Occupancy & Activation
PET occupancy studies in animals advance the understanding of
binding kinetics, which can be translated to humans, assuming that the
involved receptor is similar. Such translational approaches led to the
discovery of brivaracetam, based on knowledge of SV2A binding
kinetics of levetiracetam (Kaminski et al., 2012). Performing a PET in
each patient is infeasible, even if it is restricted to only refractory or
pharmacoresistant patients. Instead, transgenic animals with human
(mutated) transporter genes could be used to explore how in vitro
binding kinetics translate to those in vivo. With sufficient studies,
models could be constructed that describe these binding kinetics based
on receptor theory (Ploeger et al., 2009). A promising alternative is the
use of PET studies to investigate receptor density and affinity directly
(Syvänen et al., 2011). Binding kinetics either from translational studies
or from human studies may then be used in the clinic to predict target
occupancy (with subsequent target activation and efficacy) based on
the individual's genetic profile, combined with PET to ensure adequate
total brain AED exposure. In vitro or in vivo data on receptor density and
affinity can be used to inform models on the relation between in vivo
binding kinetics, target occupancy and effect profiles (de Witte et al.,
2015).
3.3. Epileptogenesis, Ictogenesis & Clinical Outcome
Advances such as next-generation sequencing, epigenetic profiling
and proteomics are leading to improved understanding of epileptogenic
and ictogenic factors (Rossignol et al., 2014). Systems biology models
based on such knowledge may one day aid in the personalisation of
AED therapy by predicting which AED will best interact with or prevent
pathological mechanisms (Loeb, 2011). On a larger scale, modelling of
the inhibitory and excitatory processes in the cortex show how their
balance breaks down during seizures (Dehghani et al., 2016). Some
neural mass and EEG models are able to describe AED side effects
(Vlooswijk et al., 2011), inter-ictal activity (Caballero-Gaudes et al.,
2013), and seizure activity (Helling et al., 2015). Due to the increase in
understanding of physiology and EEG, PEEG-based personalised med-
icine may become a reality in the near future (Swatzyna et al., 2015),
and may also prevent AED-related neurotoxicity (Salinsky et al., 2002).
To avoid the binarisation of treatment effect, seizure count models
connect an underlying parameter to efficacy (Plan, 2014). Recently, the
use of stochastic differential equations was proposed to model intra-
individual variability in this parameter, allowing further exploration of
Table 1
Currently available biomarkers in epilepsy research and development, categorised per type.
Gaps exist in all types, but especially types 2 and 3 are underrepresented. Development of current biomarkers is aimed at those biomarkers that translate directly into a factor of clinical
response (i.e. reduction in seizures, prediction of non-responders) while disregarding the intermediate steps with regard to pharmacology. PK/PD modelling methodologies that help
improve or supplant biomarkers in that area are shown in brackets.
Type 0 genotype or phenotype Type 1 drug
concentration



























CD40 interleukins oxidative stress [(PB)PK modelling] PET PEEG PEEG PEEG Responder vs non-
responder
miRNA PET Side effect measures
Na+ – Sodium channel. Ca2+ – Calcium channel. K+ – Potassium channel. GABA – gamma-aminobutyric acid channel. CD40 – cluster of differentiation 40. miRNA –microRNA. PEEG –
pharmaco-electro-encephalogram. CSF – cerebrospinal fluid. PET – positron emission tomography. cAMP – cyclic adenosine monophosphate. fMRI – functional magnetic resonance
imaging. DWI – diffusion weighted imaging. DTI – diffusion tensor imaging. vs – versus.
Fig. 3. A diagram of the scale span of the main discussed biomarkers. A large gap exists
between the microscopic and macroscopic scale, where only pharmaco-EEG and model-
ling methodologies may provide a bridge.
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trends in disease progression (Deng et al., 2016). The lack in the
modelling of AED side effects needs to be addressed, as they have a
large impact on treatment cessation and non-adherence. Ideally, models
will become available that correlate exposure to both response and side
effects, which -as part of a benefit-risk balance- allow patient and
physician to make the most informed decision (Bellanti et al., 2015).
4. Conclusions
We categorised the available epilepsy biomarkers using a biomarker
classification system (Danhof et al., 2005), and identified gaps
(Table 1). Biomarkers are lacking which provide more overlap between
each other in scale (Fig. 3). Subsequently, we provided examples of
advances in systems biology and systems pharmacology that can make
better use of -, or even supplant biomarkers. Some of the most pertinent
issues in the field of epilepsy pharmacotherapy are: being able to target
specific mutations or receptors, to predict disease progression, and to
achieve synergy by combining specific AEDs. For this to be achieved,
more quantitative biomarker models are needed.
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